Eli Lilly and Company $LLY Position Increased by Kentucky Retirement Systems

Kentucky Retirement Systems increased its holdings in Eli Lilly and Company (NYSE:LLY) by 62.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 81,856 shares of the company’s stock after acquiring an additional 31,556 shares during the quarter. Eli Lilly and Company makes up 2.6% of Kentucky Retirement Systems’ portfolio, making the stock its 4th biggest position. Kentucky Retirement Systems’ holdings in Eli Lilly and Company were worth $75,289,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Bull Harbor Capital LLC bought a new stake in shares of Eli Lilly and Company in the first quarter worth $1,675,000. Strategic Investment Advisors MI boosted its stake in Eli Lilly and Company by 29.1% during the 1st quarter. Strategic Investment Advisors MI now owns 2,615 shares of the company’s stock valued at $2,396,000 after acquiring an additional 590 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in Eli Lilly and Company during the 1st quarter valued at $3,090,000. Arkadios Wealth Advisors lifted its position in shares of Eli Lilly and Company by 4.9% during the first quarter. Arkadios Wealth Advisors now owns 29,156 shares of the company’s stock worth $26,817,000 after purchasing an additional 1,363 shares during the last quarter. Finally, IFS Group LLC acquired a new position in Eli Lilly and Company in the first quarter worth about $476,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on LLY. Guggenheim upped their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Berenberg Bank lifted their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research report on Monday, June 22nd. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Finally, Jefferies Financial Group lifted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,210.32 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business has a 50 day moving average of $1,148.72 and a two-hundred day moving average of $1,042.77. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45. The company has a market cap of $1.14 trillion, a P/E ratio of 43.00, a PEG ratio of 1.52 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.34 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 34.91 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s pipeline beyond its GLP-1 weight-loss franchise—including oncology and other newer medicines—is expected to support future growth and diversify the business. Analysts also point to several potentially important programs moving through development. Lilly pipeline article
• Positive Sentiment: The company’s $2.8 billion acquisition of AtaiBeckley expands its presence in emerging psychedelic-based mental-health treatments, signaling that Lilly is investing beyond its current GLP-1 leadership. Lilly AtaiBeckley acquisition article
• Positive Sentiment: Expansion of research and development activity in China, along with plans for a new Lehigh Valley manufacturing plant, could strengthen Lilly’s global research and production capacity. Lilly China R&D article
• Neutral Sentiment: Lilly is one of the market’s most closely watched companies in next week’s earnings slate. The report may be a near-term catalyst, particularly as investors assess demand for its GLP-1 medicines and progress in its broader portfolio. Week ahead earnings preview
• Negative Sentiment: Pre-earnings estimates are mixed. Zacks says Lilly may lack the indicators typically associated with an earnings beat, while Erste Group reduced its FY2026 EPS forecast to $35.34 from $36.33. That caution may be weighing on the stock ahead of results. Lilly earnings expectations

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.